{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:01:14Z","timestamp":1779357674483,"version":"3.51.4"},"reference-count":11,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:p>We describe the case of a 16-year-old boy with a 1-year history of severe benzodiazepine misuse. After being denied access to several treatment programs and hospital centers that felt unprepared to manage benzodiazepine use disorder and withdrawal in an adolescent, the patient was admitted to a tertiary pediatric unit for rapid inpatient tapering and detoxification. The patient was hospitalized for 13 days and received decreasing doses of diazepam under close monitoring of withdrawal symptoms. The taper was well tolerated, and the patient was transferred to a youth residential substance use treatment center, where he completed a successful 2-month placement. This case highlights the lack of adolescent-friendly facilities allowing safe tapering of rapid-acting benzodiazepines in North America. Given high rates of benzodiazepine misuse among youth and the risks associated with benzodiazepine misuse and withdrawal, there is a critical need for more research, provider training, and dedicated resources in this area.<\/jats:p>","DOI":"10.1542\/peds.2020-1085","type":"journal-article","created":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T21:25:29Z","timestamp":1608758729000},"source":"Crossref","is-referenced-by-count":7,"title":["Severe Benzodiazepine Use Disorder in a 16-Year-Old Adolescent: A Rapid and Safe Inpatient Taper"],"prefix":"10.1542","volume":"147","author":[{"given":"Camille","family":"Fournier","sequence":"first","affiliation":[{"name":"Division of Adolescent Medicine, Department of Paediatrics, Sainte-Justine University Hospital Centre, University of Montreal, Montreal, Quebec, Canada; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Jamoulle","sequence":"additional","affiliation":[{"name":"Division of Adolescent Medicine, Department of Paediatrics, Sainte-Justine University Hospital Centre, University of Montreal, Montreal, Quebec, Canada; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Chadi","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Chadi","sequence":"additional","affiliation":[{"name":"Division of Adolescent Medicine, Department of Paediatrics, Sainte-Justine University Hospital Centre, University of Montreal, Montreal, Quebec, Canada; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2021,1,1]]},"reference":[{"key":"2021120907043186100_B1","article-title":"Government of South Australia.","author":"Health"},{"issue":"7","key":"2021120907043186100_B2","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/15563650.2019.1674321","article-title":"Child and adolescent benzodiazepine exposure and overdose in the United States: 16 years of poison center data","volume":"58","author":"Friedrich","year":"2020","journal-title":"Clin Toxicol (Phila)"},{"key":"2021120907043186100_B3","volume-title":"Key Substance Use and Mental Health Indicators in the United States: Results From the 2018 National Survey on Drug Use and Health","author":"Substance Abuse and Mental Health Services Administration","year":"2019"},{"key":"2021120907043186100_B4","volume-title":"Sedatives (Canadian Drug Summary)","author":"Canadian Centre on Substance Use and Addiction","year":"2019"},{"issue":"1","key":"2021120907043186100_B5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/24734306.2019.1661568","article-title":"Clonazolam: a novel liquid benzodiazepine","volume":"3","author":"Murphy","year":"2019","journal-title":"Toxicol Commun"},{"issue":"1","key":"2021120907043186100_B6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/ADM.0000000000000350","article-title":"A review of alprazolam use, misuse, and withdrawal","volume":"12","author":"Ait-Daoud","year":"2018","journal-title":"J Addict Med"},{"issue":"12","key":"2021120907043186100_B7","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1111\/j.1360-0443.2011.03563.x","article-title":"Benzodiazepines revisited\u2013will we ever learn?","volume":"106","author":"Lader","year":"2011","journal-title":"Addiction"},{"issue":"34","key":"2021120907043186100_B8","doi-asserted-by":"crossref","first-page":"737","DOI":"10.15585\/mmwr.mm6834a2","article-title":"Changes in opioid-involved overdose deaths by opioid type and presence of benzodiazepines, cocaine, and methamphetamine - 25 states, July-December 2017 to January-June 2018","volume":"68","author":"Gladden","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"2021120907043186100_B9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0740-5472(94)90042-6","article-title":"Treatment of alprazolam withdrawal with chlordiazepoxide substitution and taper","volume":"11","author":"Closser","year":"1994","journal-title":"J Subst Abuse Treat"},{"key":"2021120907043186100_B10","author":"World Health Organization","year":"2009","journal-title":"Clinical Guidelines for Withdrawal Management and Treatment of Drug Dependence in Closed Setting"},{"key":"2021120907043186100_B11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1192\/bjp.189.3.213","article-title":"Strategies for discontinuing long-term benzodiazepine use: meta-analysis","volume":"189","author":"Voshaar","year":"2006","journal-title":"Br J Psychiatry"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2020-1085\/1082520\/peds_20201085.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2020-1085\/1082520\/peds_20201085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T01:26:24Z","timestamp":1639099584000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/147\/1\/e20201085\/33519\/Severe-Benzodiazepine-Use-Disorder-in-a-16-Year"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1,1]]},"published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2020-1085","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,1]]},"article-number":"e20201085"}}